Discussion
An experimental inhaled therapy that aims to ease respiratory symptoms in people with cystic fibrosis (CF) has won orphan drug status in the European Union — a designation designed to speed the development of new medications for rare diseases. An arm of the European Medicines Agency (EMA) granted…
